Democrats May Be Wary of Pushing Forward Trump’s Revamped International Reference Pricing Rule
Medicare actuaries indicate the ‘most-favored nations’ plan could limit patients’ access to medicine, though CMS’ Verma says she has confidence manufacturers won’t let that happen. Loss of access, combined with expected legal challenges, may make Democrats wary of embracing the Trump team’s last-minute rule, despite general agreement on the underlying policy idea. A Part D reference pricing policy is still in the works, CMS said.
You may also be interested in...
CMS Scraps ‘Most Favored Nation’ Rule To Lower Medicare Part B Drug Costs
US Centers For Medicare and Medicaid Services doesn’t tip its hand on what, if anything, might replace the rule but says it is exploring ways to lower spending on Medicare Part B drugs.
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
As Pricing Scrutiny Turns To Physician-Administered Drugs, PhRMA Points To Supply Chain Culprits
Hospital receive an average of 2.5 times what they pay for drugs in reimbursement from commercial payers, a white paper released by the trade group reports. And consolidation has increased the leverage hospitals wield in payment negotiations.